Australian life sciences company (ASX:OPT) has reported negative outcomes from its pivotal Phase 3 clinical trial involving the combination of its sozinibercept with Bayer's EYLEA (aflibercept) for treating wet age-related macular degeneration. …
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - - Latest News -
UK companies are granted more time to decide on pricing agreement
September 29, 2025 - - Latest News -
Anatara strengthens board with the appointment of Dirk van Dissel
September 29, 2025 - - Australian Biotech -
CLINUVEL advances next-generation peptide drug formulations
September 29, 2025 - -
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 - - Australian Biotech -
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - - Latest News -
Chimeric reports encouraging early data from CHM CDH17 trial
September 29, 2025 - - Australian Biotech